Julius Lindblom

Publications
CV
Public outreach and news

Articles

Article: RHEUMATOLOGY. 2024;63(9):2494-2502
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity
Nikolopoulos D; Cetrez N; Lindblom J; Palazzo L; Enman Y; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(7):889-900
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers J-O; Genre F; Hiepe F; Gerosa M; Kovacs L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; Alarcon-Riquelme ME; Beretta L
Article: RHEUMATOLOGY. 2024;63(3):798-808
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(24):7542
COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus
Dey M; Doskaliuk B; Lindblom J; Nikiphorou E; Wincup C; Fathima M; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Kadam E; Lilleker JB; Nune A; Pauling JD; Agarwal V; Dey D; Toro Gutierrez CE; Caballero CV; Chinoy H; Aggarwal R; Agarwal V; Gupta L; Parodis I
Article: RHEUMATOLOGY. 2023;62(12):3916-3923
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: CLINICAL IMMUNOLOGY. 2023;254:109713
Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics
Titus ASCLS; Tan Y; Tran P; Lindblom J; Ivbievbiokun M; Xu Y; Zheng J; Parodis I; Cai Q; Chang A; Chen S-H; Zhao M; Mohan C
Article: KIDNEY INTERNATIONAL REPORTS. 2023;8(9):1822-1830
Effect of Belimumab on Preventing de novo Renal Lupus Flares
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau FA; Sjoewall C; Rovin BH
Article: RHEUMATOLOGY. 2023;62(7):2366-2376
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis
Naveen R; Parodis I; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Nune A; Shinjo SK; Salim B; Ziade N; Velikova T; Edgar Gracia-Ramos A; Saavedra MA; Day J; Makol A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Nikiphorou E
Article: RHEUMATOLOGY. 2023;62(7):2453-2463
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
Naveen R; Nikiphorou E; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Salim B; Ziade N; Velikova T; Gracia-Ramos AE; Kuwana M; Day J; Makol A; Distler O; Chinoy H; Traboco LS; Wibowo SAK; Tehozol EAZ; Serrano JR; Garcia-De La Torre I; Aggarwal R; Gupta L; Agarwal V; Parodis I
Article: JOURNAL OF AUTOIMMUNITY. 2023;136:103025
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Parodis I
Article: FRONTIERS IN MEDICINE. 2023;10:1247354
Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
Borg A; Lindblom J; Gomez A; Soltani A; Enman Y; Heintz E; Regardt M; Grannas D; Emamikia S; Parodis I
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1257085
Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus
Lindblom J; Beretta L; Borghi MO; Alarcon-Riquelme ME; Parodis I
Article: RHEUMATOLOGY. 2022;61(12):4752-4762
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):13941
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Lindblom J; Chow JW; Sjowall C; Sciascia S; Gatto M
Article: JOURNAL OF CRANIOFACIAL SURGERY. 2022;33(2):463-468
The Volume Difference Along the External Surface of the Zygomatic Bone: A Novel Method of Measuring Zygomatic Bone Asymmetry
Rahbin S; Toufani T; Al-Khabbaz A-M; Lindblom J; Sunnergren O; Darabi H; Qureshi AR; Alinasab B
Article: BRAIN SCIENCES. 2022;12(2):192
Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
Lindblom J; Mohan C; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:1092325
EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
Lindblom J; Zetterberg S; Emamikia S; Borg A; von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:852162
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
Parodis I; Gomez A; Lindblom J; Chow JW; Doria A; Gatto M
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:796508
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Article: RHEUMATOLOGY. 2021;60(10):4703-4716
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
Lindblom J; Gomez A; Borg A; Emamikia S; Ladakis D; Matilla J; Pehr M; Cobar F; Enman Y; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4205-4217
Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
Borg A; Gomez A; Cederlund A; Cobar F; Qiu V; Lindblom J; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: FRONTIERS IN MEDICINE. 2021;8:651249
Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
Gomez A; Qiu V; Cederlund A; Borg A; Lindblom J; Emamikia S; Enman Y; Lampa J; Parodis I
Show more

All other publications

Corrigendum: JOURNAL OF AUTOIMMUNITY. 2023;140:103052
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus (vol 136, 103025, 2023)
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Parodis I
Review: JOURNAL OF CLINICAL MEDICINE. 2022;11(19):5759
Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature
Palazzo L; Lindblom J; Mohan C; Parodis I
Review: CURRENT OPINION IN RHEUMATOLOGY. 2022;34(2):139-149
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights
Lindblom J; Mohan C; Parodis I

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI